Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02848300|
Recruitment Status : Completed
First Posted : July 28, 2016
Last Update Posted : October 26, 2016
|Condition or disease||Intervention/treatment||Phase|
|Androgenetic Alopecia||Drug: Bimatoprost 1% Formulation A Drug: Bimatoprost 1% Formulation B||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Evaluation of Local Pharmacokinetics and Tolerability of Bimatoprost Applied Topically to the Scalp of Male Patients With Androgenetic Alopecia|
|Study Start Date :||July 2016|
|Actual Primary Completion Date :||October 2016|
|Actual Study Completion Date :||October 2016|
Experimental: All Participants
Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
Drug: Bimatoprost 1% Formulation A
Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
Drug: Bimatoprost 1% Formulation B
Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
- Drug Concentration in Skin Biopsy Samples [ Time Frame: Day 14 ]
- Percentage of Participants with at Least 1 Treatment Emergent Adverse Event [ Time Frame: 28 Days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02848300
|United States, Texas|
|Austin, Texas, United States, 78759|
|Study Director:||Danielle McGeeney||Allergan|